PartitionBio

PartitionBio is an early-stage biotechnology company pioneering a next-generation, non-viral delivery platform based on engineered biomolecular condensates. Its flagship product, BubbleFect, is designed as a simple, stable, and versatile reagent for the intracellular delivery of large macromolecules, targeting critical bottlenecks in research, drug discovery, and ultimately, genetic medicine. The company's mission is to democratize access to advanced therapies by reducing the cost and complexity of delivery, with initial focus on enabling faster research and scalable gene therapy development. Its platform holds potential across functional genomics, CRISPR editing, and therapeutic delivery applications.

BubbleFect: A non-viral intracellular delivery platform using engineered biomolecular condensates (membrane-less compartments formed via phase separation) for safe, room-temperature-stable delivery of diverse cargos including nucleic acids, proteins, CRISPR complexes, and insoluble small molecules.

PartitionBio competes in the non-viral delivery space against established players offering lipid nanoparticles (e.g., from companies like Acuitas, Genevant), polymers, and peptides, as well as numerous other startups. Its primary differentiation is the novel use of engineered biomolecular condensates, claiming advantages in simplicity, cargo versatility, room-temperature stability, and low cytotoxicity.